Schechter Investment Advisors LLC Has $446,000 Stake in Dr. Reddy’s Laboratories Limited (NYSE:RDY)

Schechter Investment Advisors LLC increased its position in Dr. Reddy’s Laboratories Limited (NYSE:RDY) by 383.2% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 28,247 shares of the company’s stock after purchasing an additional 22,401 shares during the period. Schechter Investment Advisors LLC’s holdings in Dr. Reddy’s Laboratories were worth $446,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Farther Finance Advisors LLC boosted its stake in Dr. Reddy’s Laboratories by 43.2% in the 3rd quarter. Farther Finance Advisors LLC now owns 454 shares of the company’s stock worth $36,000 after purchasing an additional 137 shares during the period. POM Investment Strategies LLC boosted its stake in Dr. Reddy’s Laboratories by 400.0% in the 4th quarter. POM Investment Strategies LLC now owns 2,275 shares of the company’s stock worth $36,000 after purchasing an additional 1,820 shares during the period. Allworth Financial LP boosted its stake in Dr. Reddy’s Laboratories by 447.8% in the 4th quarter. Allworth Financial LP now owns 2,728 shares of the company’s stock worth $41,000 after purchasing an additional 2,230 shares during the period. Sierra Ocean LLC acquired a new position in Dr. Reddy’s Laboratories in the 4th quarter worth approximately $43,000. Finally, Independence Bank of Kentucky boosted its stake in Dr. Reddy’s Laboratories by 400.0% in the 4th quarter. Independence Bank of Kentucky now owns 2,775 shares of the company’s stock worth $44,000 after purchasing an additional 2,220 shares during the period. Institutional investors and hedge funds own 3.85% of the company’s stock.

Dr. Reddy’s Laboratories Trading Up 0.8 %

Shares of NYSE:RDY opened at $12.92 on Thursday. The firm has a fifty day moving average of $14.34 and a two-hundred day moving average of $15.00. The firm has a market capitalization of $10.78 billion, a P/E ratio of 20.57 and a beta of 0.50. Dr. Reddy’s Laboratories Limited has a 12-month low of $12.62 and a 12-month high of $16.89. The company has a quick ratio of 1.38, a current ratio of 1.92 and a debt-to-equity ratio of 0.02.

Dr. Reddy’s Laboratories (NYSE:RDY) last released its quarterly earnings data on Thursday, January 23rd. The company reported $0.20 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.19 by $0.01. Dr. Reddy’s Laboratories had a net margin of 17.25% and a return on equity of 17.87%. On average, equities analysts expect that Dr. Reddy’s Laboratories Limited will post 0.8 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the stock. Nomura lowered shares of Dr. Reddy’s Laboratories from a “buy” rating to a “neutral” rating in a research note on Thursday, December 19th. StockNews.com lowered shares of Dr. Reddy’s Laboratories from a “buy” rating to a “hold” rating in a research note on Friday, December 6th. Finally, Barclays decreased their target price on shares of Dr. Reddy’s Laboratories from $17.40 to $17.00 and set an “overweight” rating for the company in a research note on Wednesday, November 6th.

Dr. Reddy’s Laboratories Company Profile

Dr. Reddy’s Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company’s Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.